Dihydroxyphenylisoindoline Amides as Orally Bioavailable Inhibitors of the Heat Shock Protein 90 (Hsp90) Molecular Chaperone
摘要:
The discovery and optimization of potency and metabolic stability of a novel class of dihyroxyphenylisoindoline amides as Hsp90 inhibitors are presented. Optimization of a screening hit using structure-based design and modification of log D and chemical structural features led to the identification of a class of orally bioavailable non-quinone-containing Hsp90 inhibitors. This class is exemplified by 14 and 15, which possess improved cell potency and pharmacokinetic profiles compared with the original screening hit.
[EN] The present invention is directed to amide resorcinol compounds and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as HSP-90 inhibitors. [FR] La présente invention concerne des composés d'amide résorcinol et leurs sels et solvates pharmaceutiquement acceptables, leur synthèse et leur utilisation en tant qu'inhibiteurs de HSP-90.
Dihydroxyphenylisoindoline Amides as Orally Bioavailable Inhibitors of the Heat Shock Protein 90 (Hsp90) Molecular Chaperone
作者:Pei-Pei Kung、Buwen Huang、Gang Zhang、Joe Zhongxiang Zhou、Jeff Wang、Jennifer A. Digits、Judith Skaptason、Shinji Yamazaki、David Neul、Michael Zientek、Jeff Elleraas、Pramod Mehta、Min-Jean Yin、Michael J. Hickey、Ketan S. Gajiwala、Caroline Rodgers、Jay F. Davies、Michael R. Gehring
DOI:10.1021/jm901209q
日期:2010.1.14
The discovery and optimization of potency and metabolic stability of a novel class of dihyroxyphenylisoindoline amides as Hsp90 inhibitors are presented. Optimization of a screening hit using structure-based design and modification of log D and chemical structural features led to the identification of a class of orally bioavailable non-quinone-containing Hsp90 inhibitors. This class is exemplified by 14 and 15, which possess improved cell potency and pharmacokinetic profiles compared with the original screening hit.